NASDAQ$AFYA
Afya Limited · Q1 2026 earnings
Q1 2026 earnings · · After market close · Investor relations
Briefing
Afya Q1 2026: R$1.01B revenue (+8.2% YoY), net income R$262M, basic EPS R$2.88 on medical education growth
Afya Limited reported unaudited interim results for the three months ended March 31, 2026, with consolidated revenue of R$1,012.7 million, up 8.2% from R$936.4 million in Q1 2025. Gross profit rose to R$698.1 million from R$653.7 million, and net income increased to R$261.8 million from R$257.0 million, with net income attributable to owners of R$257.0 million. Basic earnings per share were R$2.88 versus R$2.79 a year earlier, and diluted EPS were R$2.85 versus R$2.76. Undergraduate programs generated R$892.5 million of revenue, continuing education R$78.9 million, and medical practice solutions R$43.4 million. Cash and cash equivalents stood at R$1,332.9 million at quarter-end versus R$1,125.4 million at December 31, 2025. The Brazilian medical education platform continued expanding its seat base and integrating recent acquisitions while maintaining strong margins across its reportable segments.
- Consolidated revenue R$1,012.7M (+8.2% YoY); net income R$261.8M; basic EPS R$2.88 vs. R$2.79 in Q1 2025.
- Undergraduate segment revenue R$892.5M; continuing education R$78.9M; medical practice solutions R$43.4M.
- Gross profit R$698.1M with gross margin expansion driven by scale across education and medical services.
- Cash and cash equivalents R$1,332.9M at March 31, 2026, up from R$1,125.4M at year-end 2025.
- Company filed interim condensed consolidated financial statements rather than a standalone press release.
Headline financials
Revenue & EPS history
Afya · Revenue · Quarterly
R$1.01B
Revenue by segment
Afya · R$1.01B total across 3 segments · Q1 2026
- UndergraduateR$892M+7.9%87.9%
- Continuing EducationR$78.9M+11.0%7.8%
- Medical Practice SolutionsR$43.4M—4.3%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-0.7%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.1%
Avg return
30 days after
52%
11 / 21 earnings
Positive
+8.9%
Q1 2020
Best reaction
-20.8%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.4% | +1.4% | — | |
| Q3 2026 | +1.2% | +2.2% | +0.7% | |
| Q2 2025 | +3.4% | +0.2% | +4.6% | |
| Q1 2025 | -3.3% | -2.1% | -9.7% | |
| Q3 2024 | -7.8% | -6.2% | -10.7% | |
| Q2 2024 | -1.8% | -2.4% | -14.1% | |
| Q1 2024 | -1.9% | +0.2% | -13.1% | |
| Q4 2023 | +3.3% | +2.2% | -18.9% | |
| Q3 2023 | +3.3% | +8.6% | +22.1% | |
| Q1 2023 | +7.3% | +6.8% | +16.6% | |
| Q4 2022 | -8.5% | -1.9% | +11.0% | |
| Q3 2022 | -4.5% | -3.7% | +2.2% | |
| Q4 2021 | -9.4% | -7.3% | +0.8% | |
| Q3 2021 | -10.9% | -2.7% | +0.5% | |
| Q1 2021 | +8.5% | +9.2% | +24.2% | |
| Q4 2020 | +6.3% | +7.1% | +4.7% | |
| Q3 2020 | -0.7% | -2.8% | -0.7% | |
| Q1 2020 | +8.9% | +9.9% | +26.3% | |
| Q4 2019 | +6.4% | +5.9% | -4.1% | |
| Q3 2019 | +3.5% | +6.5% | -1.5% | |
| Q2 2019 | -20.8% | -22.3% | -19.7% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro